Please cite this article in press as: Pizzamiglio C, et al. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiologie Clinique/Clinical Neurophysiology (2019), https://doi.org/10.1016/j.neucli.2019.12.001 ARTICLE IN PRESS +Model NEUCLI-2682; No. of Pages 8 Neurophysiologie Clinique/Clinical Neurophysiology (2019) xxx, xxx—xxx Disponible en ligne sur ScienceDirect www.sciencedirect.com ORIGINAL ARTICLE Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients Chiara Pizzamiglio a,1 , Paolo Ripellino b,1 , Paolo Prandi c , Nausicaa Clemente d , Chiara Saggia e , Valentina Rossi e , Gionata Strigaro a,c,* , Pier Luigi Foglio Bonda f , Cristoforo Comi a,1 , Roberto Cantello a,c,1 a Department of Translational Medicine, Section of Neurology, University of Piemonte-Orientale, Via Solaroli 17, 28100 Novara, Italy b Department of Neurology, Neurocenter of Southern-Switzerland, Via Tesserete 46, 6900 Lugano, Switzerland c Department of Neurology, ‘‘Maggiore della Carità’’ University Hospital, Corso-Mazzini 18, 28100 Novara, Italy d Department of Health Sciences, University of Piemonte Orientale, Via Solaroli 17, 28100 Novara, Italy e Medical Oncology, ‘‘Maggiore della Carità’’ University Hospital, Corso-Mazzini 18, 28100 Novara, Italy f Department of Translational Medicine, University of Piemonte Orientale, Via Solaroli 17, 28100 Novara, Italy Received 22 July 2019; accepted 9 December 2019 KEYWORDS Polyneuropathy; Taxanes; Nerve conduction studies; Osteopontin; Breast cancer Summary Objective. — Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling complication related to taxanes. Underlying mechanisms are not completely understood and no specific treatment exists. We investigated the role of nerve conduction studies (NCS) and of serum osteopontin (OPN) measurement as a means to stratify the risk of developing taxane-induced neuropathy (TIN). Methods. — We enrolled 50 women with breast cancer treated with taxanes (docetaxel or pacli- taxel) in a 3-month prospective study. They were evaluated before chemotherapy (time-point T0) and followed up at 1 (T1) and 3 (T2) months with clinical examinations/scales, quality of life (QoL) questionnaires, NCS, and serum OPN dosages. Results. — A reduction of sural and superficial peroneal sensory action potentials was seen at T1, with a progression at T2 (P < 0.001). In contrast, a significant impact of neu- ropathic symptoms on QoL only occurred at T2 (P < 0.01). OPN levels at T0 inversely correlated to axonal loss in the sural nerve (T0—T2, P < 0.01). OPN levels at T0 were ∗ Corresponding author. E-mail address: gionata.strigaro@gmail.com (G. Strigaro). 1 These authors contributed equally to the present research. https://doi.org/10.1016/j.neucli.2019.12.001 0987-7053/© 2019 Elsevier Masson SAS. All rights reserved.